Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Risk-Reducing Options for High-Grade Serous Gynecologic Malignancy in BRCA1/2.

Current oncology (Toronto, Ont.) - 21 Mar 2022

Clarfield Lauren, Diamond Laura, Jacobson Michelle

Abstract excerpt

Ovarian cancer (OC) is the leading cause of death among women with gynecologic malignancy. Breast Cancer Susceptibility Gene 1 (BRCA 1) and Breast Cancer Susceptibility Gene 2 (BRCA 2) germline mutations confer an estimated 20 to 40 times increased risk of OC when compared to the general population. The majority of BRCA-associated OC is identified in the late stage, and no effective screening method has been...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA1 Protein
Share to Breast Neoplasms
Share to Genes, BRCA1

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genes, BRCA2

Share to Mutation

Share to Ovarian Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 35323372
DOI: 10.3390/curroncol29030172
PMCID: PMC8946924

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Risk-Reducing Options for High-Grade Serous Gynecologic Malignancy in BRCA1/2.PMID 35323372Read ↗

Cancer Risk-Reducing Opportunities in Gynecologic Surgery.Semantic proximity Read ↗

Risk-reducing salpingectomy: Let us be opportunistic.Semantic proximity Read ↗

Hereditary Women's Cancer: Management and Risk-Reducing Surgery.Semantic proximity Read ↗

Salpingectomy in individuals at high risk for tubo-ovarian cancer: consensus and precaution.Semantic proximity Read ↗

Hormone therapy after risk-reducing surgery in patients with BRCA1/BRCA2 mutation: evaluation of potential benefits and safety.Semantic proximity Read ↗

Risk-Reducing Strategies for Ovarian Cancer in BRCA Mutation Carriers: A Balancing Act.Semantic proximity Read ↗

Interventions to reduce the risk of ovarian and fallopian tube cancer: A European Menopause and Andropause Society Postition Statement.Semantic proximity Read ↗

Hormone therapy (HT) in women with gynecologic cancers and in women at high risk for developing a gynecologic cancer: A Society of Gynecologic Oncology (SGO) clinical practice statement: This practice statement has been endorsed by The North American Menopause Society.Semantic proximity Read ↗

Ten-point guide on the management of healthy women carrying BRCA1/2 mutations.Semantic proximity Read ↗

Risk-reducing bilateral salpingo-oophorectomy in women with BRCA1 or BRCA2 mutations.Semantic proximity Read ↗

Risk-reducing salpingectomy with delayed oophorectomy to prevent ovarian cancer in women with an increased inherited risk: insights into an alternative strategy.Semantic proximity Read ↗

Prevention of Ovarian Cancer: Where are We Now and Where are We Going?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.